OnDemand WTP Pricing Research

U.S. lawmakers push Mylan, Teva over drug pricing probe | Reuters

WASHINGTON (Reuters) – The head of the U.S. House of Representative’s oversight panel on Wednesday called on three drugmakers to turn over documents as part of an ongoing congressional review over generic drug price increases and accused the companies of “apparent efforts to stonewall” the probe.

FILE PHOTO: The logo of Teva Pharmaceutical Industries in Tel Aviv, Israel February 19, 2019. REUTERS/Amir Cohen
U.S. House Oversight Chairman Elijah Cummings, along with U.S. Senator Bernie Sanders, the ranking member on the Senate Budget Committee, sent the letters to Mylan NV (MYL.O), Teva Pharmaceutical Industries Ltd (TEVA.TA) and privately held Heritage Pharmaceuticals, the lawmakers said in a statement.

Mylan’s shares fell 7.7% to $18.20 and Teva’s U.S.-listed shares slid 8% to $6.48 in late-morning trade.

Mylan denied obstructing the inquiry and said it was prepared to make its case in a court of law, while Teva said it continues to fully cooperate with the investigations.

Read complete article here:

U.S. lawmakers push Mylan, Teva over drug pricing probe – Reuters.

Post a Comment

WP-SpamFree by Pole Position Marketing